ISIN: GB0055696032 WKN: 917990 Antisoma is a biopharmaceutical company focused on cancer drug development.
27.12.2011 - 16:18:34Antisoma. The Company?s shares are traded on NASDAQ Europe, the pan-European stock exchange, and on the London Stock Exchange, where they are included in the techMARK 100 index.
>
>Established in 1988, Antisoma has in-licensed much of its intellectual property, including clinical development candidates pemtumomab (formerly known as Theragyn) and Therex, from cancer research and other academic institutions.
>
>Antisoma fills its development pipeline by acquiring promising early stage cancer products from both academic and commercial institutions rather than from in-house research. Antisoma's core activity is the management of pre-clinical and clinical development to demonstrate the safety and efficacy of drug candidates. Generally pharmaceutical partners will complete clinical development, filing for regulatory approval and marketing. This strategy is demonstrated by the progress of Antisoma's lead product, pemtumomab (formerly known as Theragyn), from an in-licensed product candidate into a Phase III study. Antisoma has signed an exclusive agreement with Abbott Laboratories to complete clinical studies and to commercialise the product worldwide.
>
>Antisoma has an experienced Board and senior management team, with individuals who have worked in both international pharmaceutical companies, including Pfizer, Hoechst, Glaxo and Medeva, and financial institutions such as KPMG, Flemings and WestLB Panmure. The Company's human resource strategy is to employ a core staff of highly-skilled individuals, currentlyaround60 persons including support staff, who manage the drug development process through a network of external collaborations and contracts with specialist companies.
>Established in 1988, Antisoma has in-licensed much of its intellectual property, including clinical development candidates pemtumomab (formerly known as Theragyn) and Therex, from cancer research and other academic institutions.
>
>Antisoma fills its development pipeline by acquiring promising early stage cancer products from both academic and commercial institutions rather than from in-house research. Antisoma's core activity is the management of pre-clinical and clinical development to demonstrate the safety and efficacy of drug candidates. Generally pharmaceutical partners will complete clinical development, filing for regulatory approval and marketing. This strategy is demonstrated by the progress of Antisoma's lead product, pemtumomab (formerly known as Theragyn), from an in-licensed product candidate into a Phase III study. Antisoma has signed an exclusive agreement with Abbott Laboratories to complete clinical studies and to commercialise the product worldwide.
>
>Antisoma has an experienced Board and senior management team, with individuals who have worked in both international pharmaceutical companies, including Pfizer, Hoechst, Glaxo and Medeva, and financial institutions such as KPMG, Flemings and WestLB Panmure. The Company's human resource strategy is to employ a core staff of highly-skilled individuals, currentlyaround60 persons including support staff, who manage the drug development process through a network of external collaborations and contracts with specialist companies.
